

CORRECTION

Open Access



Correction: Expression of ADAM15 in rheumatoid synovium: up-regulation by vascular endothelial growth factor and possible implications for angiogenesis

Koichiro Komiya^{1,2}, Hiroyuki Enomoto², Isao Inoki¹, Satoko Okazaki¹, Yoshinari Fujita^{1,2}, Eiji Ikeda¹, Eiko Ohuchi³, Hideo Matsumoto², Yoshiaki Toyama² and Yasunori Okada^{1*}

Correction: Arthritis Res Ther 7, R1158 (2005)
<https://doi.org/10.1186/ar1796>

Following publication of the original article [1], an error was identified in Figs. 2 and 5. The correct figures are given below.

In addition, since the publication of the original article [1], it has come to our attention that we failed to include information for one of the authors in the competing interests section. The full competing interests section for this article can be found below.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13075-022-02936-1>.

Additional file 1. Supplementary figures.

Author details

¹Department of Pathology, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan. ²Department of Orthopaedic Surgery, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan. ³Biopharmaceutical Department, Daiichi Fine Chemical Co. Ltd., Takaoka, Toyama, Japan.

Published online: 01 November 2022

Reference

1. Komiya K, Enomoto H, Inoki I, et al. Expression of ADAM15 in rheumatoid synovium: up-regulation by vascular endothelial growth factor and possible implications for angiogenesis. *Arthritis Res Ther*. 2005;7:R1158. <https://doi.org/10.1186/ar1796>.

Declarations

Competing interests

Eiko Onuchi is affiliated with Daiichi Fine Chemical Co and developed the monoclonal antibody used in the experiment. The authors have no other competing interests to disclose.

The original article can be found online at <https://doi.org/10.1186/ar1796>.

*Correspondence: okada@z6.keio.jp

¹ Department of Pathology, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 2 mRNA expression of ADAM species in rheumatoid arthritis (RA) and osteoarthritis (OA) synovial samples. Total RNA was extracted from RA or OA synovial tissue samples, and reverse transcribed into cDNA, followed by PCR as described in Materials and methods. Results from representative six RA (lanes 1-6) and six OA (lanes 7-12) synovial samples are shown. Although sample numbers of RA and OA cases were reduced from eight to six, the data in this corrected version of Fig. 2 are confirmatory to those in the original Fig. 2. C, positive controls. The cropped gel images in the corrected Fig. 2 are delineated, and the uncropped images for ADAM species and β-actin (full-length gels) are uploaded as [ESM](#)




Fig. 5 Immunolocalization of ADAM15, VEGFR-2, vWF and CD31 in rheumatoid arthritis (RA) synovial tissues. Paraffin sections were stained with **a** hematoxylin and eosin or immunostained with antibodies against **b** ADAM15, **c** VEGFR-2, **d** vWF or **e** CD31, or **f** non-immune mouse IgG as described in Materials and methods. Note that ADAM15 is expressed in synovial lining cells and endothelial cells of blood vessels in the sublining layer (**b**). Immunostained sections were counterstained with hematoxylin. Arrows, synovial lining cells; arrowheads, endothelial cells of blood vessel. Scale bar, 100 μ m